AstraZeneca $AZN Q2 profit beats estimates on oncology surge
AstraZeneca $AZN Q2 profit beats estimates on oncology surgeAstraZeneca’s second-quarter print gave $AZN investors a clear bullish catalyst this morning: core profit topped analyst estimates, and the ...